198 related articles for article (PubMed ID: 36959063)
1. Innovative treatments for meningiomas.
Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
[TBL] [Abstract][Full Text] [Related]
2. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
Graillon T; Tabouret E; Chinot O
Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
[TBL] [Abstract][Full Text] [Related]
4. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
5. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
8. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Graillon T; Defilles C; Mohamed A; Lisbonis C; Germanetti AL; Chinot O; Figarella-Branger D; Roche PH; Adetchessi T; Fuentes S; Metellus P; Dufour H; Enjalbert A; Barlier A
J Neurooncol; 2015 Aug; 124(1):33-43. PubMed ID: 26015296
[TBL] [Abstract][Full Text] [Related]
10. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF
Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059
[TBL] [Abstract][Full Text] [Related]
11.
Das A; Martinez Santos JL; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Cancer Invest; 2020 Jul; 38(6):349-355. PubMed ID: 32441531
[No Abstract] [Full Text] [Related]
12. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.
Johnson MD; O'Connell MJ; Pilcher W; Reeder JE
J Neurosurg; 2010 May; 112(5):934-9. PubMed ID: 19698046
[TBL] [Abstract][Full Text] [Related]
13. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
14. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
15. Genomic landscape of intracranial meningiomas.
Bi WL; Abedalthagafi M; Horowitz P; Agarwalla PK; Mei Y; Aizer AA; Brewster R; Dunn GP; Al-Mefty O; Alexander BM; Santagata S; Beroukhim R; Dunn IF
J Neurosurg; 2016 Sep; 125(3):525-35. PubMed ID: 26771848
[TBL] [Abstract][Full Text] [Related]
16. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
17. [The Potential of Personalized/Precision Medicine for Meningiomas].
Yamaguchi S; Fujimura M
No Shinkei Geka; 2022 Jan; 50(1):132-140. PubMed ID: 35169093
[TBL] [Abstract][Full Text] [Related]
18. Activation of multiple growth factor signalling pathways is frequent in meningiomas.
Hilton DA; Shivane A; Kirk L; Bassiri K; Enki DG; Hanemann CO
Neuropathology; 2016 Jun; 36(3):250-61. PubMed ID: 26554033
[TBL] [Abstract][Full Text] [Related]
19. Current treatment options for meningioma.
Apra C; Peyre M; Kalamarides M
Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
[TBL] [Abstract][Full Text] [Related]
20. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K
Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]